Occurrence of Circulating Antibodies against the Hemagglutinins of Influenza Viruses in the 2022/2023 Epidemic Season in Poland

Katarzyna Kondratiuk; Anna Poznańska; Karol Szymański; Emilia Czajkowska; Bartosz Mańkowski; Lidia B. Brydak

doi:10.3390/v16071105

Viruses (Jul 2024)

Occurrence of Circulating Antibodies against the Hemagglutinins of Influenza Viruses in the 2022/2023 Epidemic Season in Poland

Katarzyna Kondratiuk,
Anna Poznańska,
Karol Szymański,
Emilia Czajkowska,
Bartosz Mańkowski,
Lidia B. Brydak

Affiliations

Katarzyna Kondratiuk: Laboratory of Influenza Viruses and Respiratory Viruses, Department of Virology, National Institute of Public Health NIH—National Research Institute, 00-791 Warsaw, Poland
Anna Poznańska: Department of Population Health Monitoring and Analysis, National Institute of Public Health NIH—National Research Institute, 00-791 Warsaw, Poland
Karol Szymański: Laboratory of Influenza Viruses and Respiratory Viruses, Department of Virology, National Institute of Public Health NIH—National Research Institute, 00-791 Warsaw, Poland
Emilia Czajkowska: Laboratory of Influenza Viruses and Respiratory Viruses, Department of Virology, National Institute of Public Health NIH—National Research Institute, 00-791 Warsaw, Poland
Bartosz Mańkowski: Laboratory of Influenza Viruses and Respiratory Viruses, Department of Virology, National Institute of Public Health NIH—National Research Institute, 00-791 Warsaw, Poland
Lidia B. Brydak: Laboratory of Influenza Viruses and Respiratory Viruses, Department of Virology, National Institute of Public Health NIH—National Research Institute, 00-791 Warsaw, Poland

DOI: https://doi.org/10.3390/v16071105
Journal volume & issue: Vol. 16, no. 7
p. 1105

Abstract

Read online

The aim of this study was to determine the level of anti-hemagglutinin antibodies in blood sera collected from patients during the 2022/2023 epidemic season in Poland. A total of 700 sera samples from patients across the country were tested. The samples were divided into seven groups according to the age of the patients, with 100 samples from each age group. The hemagglutination inhibition test (OZHA) was used to determine the level of anti-hemagglutinin antibodies. The test results have confirmed the presence of anti-hemagglutinin antibodies for antigens A/Victoria/2570/2019 (H1N1)pdm09, A/Darwin/9/2021 (H3N2), B/Austria/1359417/2021 (B/Yamagata lineage) and B/ Phuket/3073/2013 (B/Victoria lineage) present in the influenza vaccine recommended by the World Health Organization (WHO) for the 2022/2023 epidemic season. The highest geometric mean antibody titres (GMT) and protection rate values (%) were recorded for hemagglutinin A/H3N2. In Poland, in the 2022/2023 epidemic season, the percentage of the population vaccinated against influenza was 5.7%. Therefore, the test results can be interpreted as the response of the immune system in patients who have been previously infected with an influenza virus.

Published in Viruses

ISSN: 1999-4915 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Science: Microbiology
Website: http://www.mdpi.com/journal/viruses

About the journal

Abstract

Keywords